Coagulation factor IXa and coagulation factor Xa (FIXa and FXa)

The term 'Coagulation factor IXa and coagulation factor Xa' does not correspond to a single molecular entity or standard single target; it appears to refer to two related yet distinct serine proteases in the coagulation cascade: factor IXa (activated form of factor IX) and factor Xa (activated form of factor X). Structured information below is presented primarily for coagulation factor Xa, given far more data in the search results, and the prominence of FXa as a direct drug target in recent drug development. Coagulation factor Xa (FXa) is a vitamin K–dependent serine protease synthesized in the liver and plays a central role in the coagulation cascade by converting prothrombin to thrombin, with the help of factor Va, calcium, and phospholipid surfaces. FXa is generated from its inactive precursor factor X (FX) via cleavage by either the intrinsic (FIXa/FVIIIa complex) or extrinsic (tissue factor/FVIIa) pathways. The active enzyme is a two-chain glycoprotein stabilized by a disulfide bond and contains a Gla domain for phospholipid binding, two EGF-like domains, and a catalytic serine protease domain. FXa not only mediates clot formation but also modulates cellular signaling (especially via protease-activated receptors PAR-1 and PAR-2), contributing to inflammatory and vascular processes as well as being a therapeutic target for anticoagulant drugs. Inherited or acquired deficiencies in FXa can result in bleeding disorders, while excessive activity promotes thrombosis. New classes of direct oral FXa inhibitors have largely replaced warfarin for many indications due to their predictability and oral convenience. Information about 'FIXa' (activated factor IX) is not fully covered in the provided search results, but it is similarly a vitamin K–dependent serine protease essential for propagation of the coagulation cascade as part of the intrinsic Xase (tenase) complex. If you require combined or equally detailed information specifically about factor IXa, clarification is recommended, as this combined entity is not canonical and should be split into separate, well-defined targets.

Other names

Factor XFactor Xa (activated form of Factor X, for FX)Stuart–Prower factor (historical, for FX)F10 (gene name for FX)

Inhibitors block the active site of FXa, thus preventing the conversion of prothrombin to thrombin and downstream clot formation. Direct FXa inhibitors exhibit competitive inhibition by binding the enzyme and blocking substrate access. Indirect inhibition occurs via depletion/inactivation, for example, warfarin reduces synthesis of vitamin K dependent factors.